Navigation Links
Oncolytic viruses mediating anti-tumor immunity in human cancer patients

The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research. The therapy program is based on scientific research at the University of Helsinki and serves as the foundation for ongoing clinical development.

The results demonstrate an anti-tumor immunity of oncolytic viruses published for the first time in humans and indicate the strong efficacy of the next generation viruses against solid tumor cancers. As of today, 200 patients have been treated with oncolytic virus therapy in the company's Advanced Therapy Access Program.

"This is the first time it has been shown in humans that oncolytic viruses can be used for the induction of anti-tumor immunity. The GMCSF armed oncolytic adenovirus can mediate anti-tumor immunologic responses by recruiting natural killer cells and by the induction of tumor-specific cytotoxic T-cells", explains research professor Akseli Hemminki, the CSO and co-founder of Oncos.

"Anti-tumor immunity plays a major role in the strong efficacy results. We are starting clinical trials with CGTG-102, which is further improved compared of the virus described in this publication", comments Pekka Simula, the CEO and co-founder of Oncos.

The Cancer Research article reports strong safety and efficacy results in patients with advanced cancer progressing after available chemotherapy options. Out of the 15 radiologically evaluable patients 2 had complete responses (13%), 5 patients had stable disease (33 %) and 1 had a partial response (6 %). Therefore, the clinical benefit rate was 47% according to the RECIST criteria. Responses were frequently seen in both injected and non-injected tumors. The safety profile was favorable with no grade 4-5 side effects realized.

"It has been impressive to see how powerful and consistent the oncolytic adenovirus platform is for directing the body's own immune system against tumor cells" says Dr. Vincenzo Cerullo, the scientist who led the project at the University of Helsinki Cancer Gene Therapy Group (CGTG).


Contact: Timo Ahopelto
University of Helsinki

Related medicine news :

1. Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
2. Mild-mannered metabolic helper rushes to fight invading viruses, researchers report
3. UBC graduate student finds a start/stop switch for retroviruses
4. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
5. Researchers find broad spectrum antiviral that fights multitude of viruses
6. Compound found that targets wide range of viruses
7. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
8. Poorly understood cell plays role in immunity against the flu
9. BHM Healthcare Congratulates PORT Human Services: First to Receive CABHA Status
10. The cost of medicalizing human conditions
11. It was brawn over beauty in human mating competition
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: